PT2073837E - Vírus vaccinia ankara modificado recombinante que codifica um antigénio her-2 em associação com um taxano para utilização no tratamento de cancro - Google Patents
Vírus vaccinia ankara modificado recombinante que codifica um antigénio her-2 em associação com um taxano para utilização no tratamento de cancro Download PDFInfo
- Publication number
- PT2073837E PT2073837E PT78393071T PT07839307T PT2073837E PT 2073837 E PT2073837 E PT 2073837E PT 78393071 T PT78393071 T PT 78393071T PT 07839307 T PT07839307 T PT 07839307T PT 2073837 E PT2073837 E PT 2073837E
- Authority
- PT
- Portugal
- Prior art keywords
- taxane
- antigen
- combination
- treating cancer
- modified vaccinia
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940123237 Taxane Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85003106P | 2006-10-06 | 2006-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2073837E true PT2073837E (pt) | 2014-09-22 |
Family
ID=39283388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78393071T PT2073837E (pt) | 2006-10-06 | 2007-10-05 | Vírus vaccinia ankara modificado recombinante que codifica um antigénio her-2 em associação com um taxano para utilização no tratamento de cancro |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7807146B2 (enExample) |
| EP (2) | EP2596801B1 (enExample) |
| JP (2) | JP5964540B2 (enExample) |
| AU (1) | AU2007307080B2 (enExample) |
| CA (1) | CA2665068C (enExample) |
| DK (2) | DK2596801T3 (enExample) |
| ES (1) | ES2500465T3 (enExample) |
| IL (1) | IL197633A (enExample) |
| NZ (2) | NZ575388A (enExample) |
| PT (1) | PT2073837E (enExample) |
| WO (1) | WO2008045346A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| NZ575388A (en) * | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
| US20110206736A1 (en) * | 2008-09-23 | 2011-08-25 | Thomas Jefferson University | Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same |
| EP2636201B1 (en) * | 2010-11-02 | 2019-02-27 | Telefonaktiebolaget LM Ericsson (publ) | Methods and devices for media description delivery |
| US9463238B2 (en) | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2908851A1 (en) * | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2777711A1 (en) * | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| JP6444398B2 (ja) | 2013-07-03 | 2018-12-26 | コニンクリーケ・ケイピーエヌ・ナムローゼ・フェンノートシャップ | セグメント化コンテンツのストリーミング |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CN111556760A (zh) * | 2017-11-06 | 2020-08-18 | 纪念斯隆-凯特林癌症中心 | 作为疫苗免疫佐剂的热灭活的牛痘病毒 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3171450A1 (fr) | 2025-01-17 | 2026-07-24 | Odimma Therapeutics | Virus enveloppé pour la transfection d’acides nucléiques exogènes. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| DE19729279A1 (de) | 1997-07-09 | 1999-01-14 | Peter Hildebrandt | Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt |
| KR100731820B1 (ko) | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| DE10042598A1 (de) | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1435965A4 (en) * | 2001-09-26 | 2005-09-21 | Intermune Inc | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| EP1558242B1 (en) * | 2002-11-06 | 2008-12-24 | Cyclacel Limited | Combination comprising docetaxel and a cdk inhibitor |
| US8663622B2 (en) * | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
| CN1511549A (zh) * | 2002-12-27 | 2004-07-14 | 张小丽 | 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物 |
| ITMI20030317A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale. |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| KR20060012622A (ko) * | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
| US7763452B2 (en) | 2003-06-25 | 2010-07-27 | Bn Immunotherapeutics, Inc. | Purification of HER-2 variants |
| MXPA05013389A (es) * | 2003-06-25 | 2006-03-17 | Pharmexa As | Purificacion de variantes her-2. |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| CN101128217B (zh) | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| NZ575388A (en) | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
-
2007
- 2007-10-05 NZ NZ575388A patent/NZ575388A/en unknown
- 2007-10-05 JP JP2009531472A patent/JP5964540B2/ja active Active
- 2007-10-05 US US11/905,876 patent/US7807146B2/en active Active
- 2007-10-05 CA CA2665068A patent/CA2665068C/en active Active
- 2007-10-05 PT PT78393071T patent/PT2073837E/pt unknown
- 2007-10-05 WO PCT/US2007/021436 patent/WO2008045346A2/en not_active Ceased
- 2007-10-05 EP EP13154196.3A patent/EP2596801B1/en active Active
- 2007-10-05 DK DK13154196.3T patent/DK2596801T3/en active
- 2007-10-05 NZ NZ597998A patent/NZ597998A/xx unknown
- 2007-10-05 DK DK07839307.1T patent/DK2073837T3/da active
- 2007-10-05 AU AU2007307080A patent/AU2007307080B2/en active Active
- 2007-10-05 ES ES07839307.1T patent/ES2500465T3/es active Active
- 2007-10-05 EP EP07839307.1A patent/EP2073837B1/en active Active
-
2009
- 2009-03-17 IL IL197633A patent/IL197633A/en active IP Right Grant
-
2010
- 2010-08-31 US US12/872,156 patent/US8313740B2/en active Active
-
2014
- 2014-03-11 JP JP2014047741A patent/JP6124822B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ575388A (en) | 2012-03-30 |
| US20080213302A1 (en) | 2008-09-04 |
| CA2665068C (en) | 2016-01-05 |
| AU2007307080A1 (en) | 2008-04-17 |
| EP2596801A1 (en) | 2013-05-29 |
| EP2073837B1 (en) | 2014-06-25 |
| US8313740B2 (en) | 2012-11-20 |
| IL197633A0 (en) | 2011-08-01 |
| DK2073837T3 (da) | 2014-09-29 |
| CA2665068A1 (en) | 2008-04-17 |
| JP2014129416A (ja) | 2014-07-10 |
| EP2596801B1 (en) | 2018-05-02 |
| US7807146B2 (en) | 2010-10-05 |
| WO2008045346A3 (en) | 2009-06-04 |
| US20110008294A1 (en) | 2011-01-13 |
| WO2008045346A2 (en) | 2008-04-17 |
| IL197633A (en) | 2017-03-30 |
| JP5964540B2 (ja) | 2016-08-03 |
| ES2500465T3 (es) | 2014-09-30 |
| NZ597998A (en) | 2013-08-30 |
| AU2007307080B2 (en) | 2014-01-09 |
| DK2596801T3 (en) | 2018-08-13 |
| EP2073837A2 (en) | 2009-07-01 |
| JP2010505850A (ja) | 2010-02-25 |
| JP6124822B2 (ja) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2073837T3 (da) | Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer | |
| PT2136633E (pt) | Terapia de cancro com vírus vacina oncolítico | |
| IL186662A0 (en) | Combination cancer therapy with | |
| GB2434763B (en) | Induction hardened blade | |
| EP1814544A4 (en) | CANCER TREATMENTS | |
| ZA201004403B (en) | Therapeutic cancer treatments | |
| EP2095220A4 (en) | POWER SUPPLIED CARDS | |
| IL238045A0 (en) | Tumor treatment with an antibody against vegf | |
| EP2178531A4 (en) | METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS | |
| GB0613360D0 (en) | Bar code authentication | |
| GB2454602B8 (en) | File system authentication | |
| EP2115568A4 (en) | DISTRIBUTED AUTHENTICATION, AUTHORIZATION AND ACCOUNTING | |
| EP2115660A4 (en) | SECURE FILE ENCRYPTION | |
| ZA201009096B (en) | Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment | |
| EP1793842A4 (en) | TREATMENT OF CANCER-RELATED FATIGUE | |
| EP1929696A4 (en) | SIGNATURE AUTHENTICATION | |
| ZA200902203B (en) | Combination therapy | |
| EP2029156A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| EP1941278A4 (en) | OPTIMAL POLYVALENT VACCINE FOR CANCER | |
| LT2139917T (lt) | Antiandrogeniniai peptidai ir jų naudojimas vėžio terapijai | |
| EP1841467A4 (en) | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES | |
| GB2428846B (en) | Prescription Authentication | |
| HUE036822T2 (hu) | CGNC alkalmazásra H. pylori fertõzésben | |
| EP1734950A4 (en) | TREATMENT OF A VIRUS DISEASE | |
| GB0413346D0 (en) | Treating cancer |